Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease

Current Drug Metabolism

Volumn 15, Issue 9, 2014, Pages 875-881

  Guerra, Iván ^a   Chaparro, María ^b   Bermejo, Fernando ^a   Gisbert, Javier P ^b  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Adalimumab; Anti TNF; Antibodies; Immunogenicity; Inflammatory bowel disease; Infliximab; Trough levels

Indexed keywords

DRUG ANTIBODY; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR INHIBITOR; ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG USE; ELIMINATION HALF-LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUID PHASE RADIOIMMUNOASSAY; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; MEASUREMENT; RADIOIMMUNOASSAY; ANTAGONISTS AND INHIBITORS; BLOOD; INFLAMMATORY BOWEL DISEASES;

ANTIBODIES; HUMANS; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930842615     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200215666141106104209     Document Type: Article

References (53)

1. Terdiman J. P., Gruss C. B., Heidelbaugh J. J., Sultan S., Falck-Ytter Y. T., Practice A. G. A. I. C., Quality Management C. American Gastroenterological Association Institute guideline on the use of thiopurines methotrexate and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013 145 1459-1463.
2. Stidham R. W., Lee T. C., Higgins P. D., Deshpande A. R., Sussman D. A., Singal A. G., Elmunzer B. J., Saini S. D., Vijan S., Waljee A. K. Systematic review with network meta-analysis: The efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment. Pharmacol. Ther., 2014 39 660-671.
3. Ben-Horin S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun. Rev., 2014 13 24-30.
4. Gisbert J. P., Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review. Am. J. Gastroenterol., 2009 104 760-767.
5. Billioud V., Sandborn W. J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: A systematic review. Am. J. Gastroenterol., 2011 106 674-684.
6. Ben-Horin S., Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment. Pharmacol. Ther., 2011 33 987-995.
7. Guerra I., Chaparro M., Bermejo F., Gisbert J. P. Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease. Curr. Drug Metab., 2011 12 594-598.
8. Cohen L. B., Nanau R. M., Delzor F., Neuman M. G. Biologic therapies in inflammatory bowel disease. Transl. Res., 2014 163 533-556.
9. Ordas I., Mould D. R., Feagan B. G., Sandborn W. J. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin. Pharmacol. Therapeut., 2012 91 635-646.
10. Lobo E. D., Hansen R. J., Balthasar J. P. Antibody pharmacokinetics and pharmacodynamics. J. Pharmaceut. Sci., 2004 93 2645-2668.
11. Fasanmade A. A., Adedokun O. J., Ford J., Hernandez D., Johanns J., Hu C., Davis H. M., Zhou H. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur. J. Clin. Pharmacol., 2009 65 1211-1228.
12. Fasanmade A. A., Adedokun O. J., Blank M., Zhou H., Davis H. M. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: A retrospective analysis of data from 2 phase III clinical trials. Clin. Therapeut., 2011 33 946-964.
13. Ternant D., Paintaud G. Pharmacokinetics and concentrationeffect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin. Biol. Ther., 2005 5 Suppl 1 S37-47.
14. Ling J., Lyn S., Xu Z., Achira M., Bouman-Thio E., Shishido A., Ford J., Shankar G., Wagner C., Kim K. T., Davis H. M., Zhou H. Lack of Racial Differences in the Pharmacokinetics of Subcutaneous Golimumab in Healthy Japanese and Caucasian Male Subjects. J. Clin. Pharmacol., 2010 50 792-802.
15. Ternant D., Aubourg A., Magdelaine-Beuzelin C., Degenne D., Watier H., Picon L., Paintaud G. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther. Drug Monit., 2008 30 523-529.
16. Ungar B., Chowers Y., Yavzori M., Picard O., Fudim E., Har-Noy O., Kopylov U., Eliakim R., Ben-Horin S., on behalf of A. c. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2013.
17. Awni W., Eckert D., Sharma S., Mostafa N., Noertersheuser P., Pradhan R., Robinson A., Sandborn W., Hanauer S., Colombel J. F., Thakkar R. P412 Pharmacokinetics of adalimumab in adult patients with moderately to severely active ulcerative colitis. J. Crohns Colitis 2013 7 S175.
18. Noertersheuser P., Eckert D., Sharma S., Thakkar R., Robinson A., Sandborn W., Hanauer S., Colombel J. F., Awni W. P493 Factors affecting adalimumab pharmacokinetics in adult patients with moderate to severe CD. J. Crohns Colitis 2013 7 S207.
19. Bendtzen K. Personalized medicine: Theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov. Med., 2013 15 201-211.
20. Steenholdt C., Ainsworth M. A., Tovey M., Klausen T. W., Thomsen O. O., Brynskov J., Bendtzen K. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther. Drug Monit., 2013 35 530-538.
21. Wang S. L., Ohrmund L., Hauenstein S., Salbato J., Reddy R., Monk P., Lockton S., Ling N., Singh S. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J. Immunol. Methods 2012 382 177-188.
22. Wang S. L., Hauenstein S., Ohrmund L., Shringarpure R., Salbato J., Reddy R., McCowen K., Shah S., Lockton S., Chuang E., Singh S. Monitoring of adalimumab and antibodies-toadalimumab levels in patient serum by the homogeneous mobility shift assay. J. Pharm. Biomed. Anal., 2013 78-79 39-44.
23. Steenholdt C., Al-khalaf M., Brynskov J., Bendtzen K., Thomsen O. O., Ainsworth M. A. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm. Bowel Dis., 2012 18 2209-2217.
24. Reinisch W., Feagan B. G., Rutgeerts P. J., Adedokun O. J., Cornillie F. J., Diamond R., Marano C. W., Sandborn W. J. 566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis. Gastroenterology 2012 142 S-114.
25. Cornillie F., Hanauer S. B., Diamond R. H., Wang J., Tang K. L., Xu Z., Rutgeerts P., Vermeire S. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: A retrospective analysis of the ACCENT I trial. Gut 2014.
26. Feagan B. G., Singh S., Lockton S., Hauenstein S., Ohrmund L., Croner L. J., Greenberg G. R., Sandborn W. J., Rutgeerts P. J., Vermeire S. 565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD). Gastroenterology 2012 142 S-114.
27. Bortlik M., Duricova D., Malickova K., Machkova N., Bouzkova E., Hrdlicka L., Komarek A., Lukas M. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J. Crohns Colitis 2013 7 736-743.
28. Casteele N. V., Gils A., Ballet V., Compernolle G., Peeters M., Steen K. V., Simoens S., Ferrante M., Assche G. V., Vermeire S., Rutgeerts P. Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT study. United European Gastroenterol. J., 2013 1 A1.
29. Casteele N. V., Compernolle G., Ballet V., Van Assche G., Gils A., Vermeire S., Rutgeerts P. J. 1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial. Gastroenterology 2012 142 S-211-S-212.
30. Mostafa N. M., Eckert D., Pradhan R. S., Mensing S., Robinson A., Sandborn W., Hanauer S. B., Colombel J.-F., Thakkar R., Awni W. M. Sa1195 Exposure-Efficacy Relationship (ER) for Adalimumab During Induction Phase of Treatment of Adult Patients With Moderate to Severe Ulcerative Colitis. Gastroenterology 2013 144 S-225-S-226.
31. Yarur A. J., Deshpande A. R., Sussman D. A., Hauenstein S., Lockton S., Barkin J. S., Singh S., Abreu M. T. Tu1147 Serum Adalimumab Levels and Antibodies Correlate With Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients With Inflammatory Bowel Disease. Gastroenterology 2013 144 S-774-S-775.
32. Velayos F. S., Sheibani S., Lockton S., Hauenstein S., Singh S., Terdiman J. P., Mahadevan U. 490 Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between Ata and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients. Gastroenterology 2013 144 S-91.
33. Roblin X., Marotte H., Rinaudo M., Del Tedesco E., Moreau A., Phelip J. M., Genin C., Peyrin-Biroulet L., Paul S. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol., 2014 12 80-84 e82.
34. Afif W., Loftus E. V., Jr., Faubion W. A., Kane S. V., Bruining D. H., Hanson K. A., Sandborn W. J. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol., 2010 105 1133-1139.
35. Yarur A. J., Abreu M. T., Deshpande A. R., Kerman D. H., Sussman D. A. Therapeutic drug monitoring in patients with inflammatory bowel disease. World J. Gastroenterol., 2014 20 3475-3484.
36. Nanda K. S., Cheifetz A. S., Moss A. C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): A meta-analysis. Am. J. Gastroenterol., 2013 108 40-47, quiz 48.
37. Hanauer S. B., Wagner C. L., Bala M., Mayer L., Travers S., Diamond R. H., Olson A., Bao W., Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol., 2004 2 542-553.
38. Seow C. H., Newman A., Irwin S. P., Steinhart A. H., Silverberg M. S., Greenberg G. R. Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010 59 49-54.
39. Baert F., Noman M., Vermeire S., Van Assche G., G D. H., Carbonez A., Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. NEMJ., 2003 348 601-608.
40. Vande Casteele N., Gils A., Singh S., Ohrmund L., Hauenstein S., Rutgeerts P., Vermeire S. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am. J. Gastroenterol., 2013 108 962-971.
41. Ben-Horin S., Mazor Y., Yanai H., Ron Y., Kopylov U., Yavzori M., Picard O., Fudim E., Maor Y., Lahat A., Coscas D., Eliakim R., Dotan I., Chowers Y. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment. Pharmacol. Ther., 2012 35 714-722.
42. Baert F., Drobne D., Gils A., Vande Casteele N., Hauenstein S., Singh S., Lockton S., Rutgeerts P., Vermeire S. Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy. Clin. Gastroenterol. Hepatol., 2014.
43. Steenholdt C., Palarasah Y., Bendtzen K., Teisner A., Brynskov J., Teisner B., Nielsen C. H. Pre-existing IgG antibodies crossreacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther., 2013 37 1172-1183.
44. Arias M. T., Vande Casteele N., Drobne D., Ferrante M., Cleynen I., Ballet V., Rutgeerts P., Gils A., Vermeire S. OP10 Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis. J. Crohns Colitis 2012 6 S5.
45. Colombel J. F., Sandborn W. J., Reinisch W., Mantzaris G. J., Kornbluth A., Rachmilewitz D., Lichtiger S., D'Haens G., Diamond R. H., Broussard D. L., Tang K. L., van der Woude C. J., Rutgeerts P., Group S. S. Infliximab azathioprine or combination therapy for Crohn's disease. New Engl. J. Med., 2010 362 1383-1395.
46. Van Schaik T., Roopram R. K., Maljaars P. W., Ipenburg N., Verwey M. H., Hardwick J. C., Veenendaal R., van der Meulen-de Jong A. E. 208 Influence of Combination Therapy With Immune Modulators on Anti-TNF Trough Levels and Antibodies in IBD Patients. Gastroenterology 2014 146 S-54.
47. Ben-Horin S., Waterman M., Kopylov U., Yavzori M., Picard O., Fudim E., Awadie H., Weiss B., Chowers Y. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol., 2013 11 444-447.
48. Echarri A., Ferreiro R., Fraga-Iriso R., Acosta M. B.-d., Cid J., De-Castro L., Pereira S., Fernández-Villaverde A., Soto S., Carpio D., Gonzalez B., Castro E., Ollero V., Campos A. C. Sa1264 Drug Trough Levels and Primary Nonresponse to antiTNF Therapy in Moderate-Severe Crohn Disease. Results of the Optimiza Study. Gastroenterology 2014 146 S-247.
49. Colombel J. F., Sandborn W. J., Allez M., Dupas J. L., Dewit O., D'Haens G., Bouhnik Y., Parker G., Pierre-Louis B., Hebuterne X. Association between plasma concentrations of certoli zumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin. Gastroenterol. Hepatol., 2014 12 423-431 e421.
50. Yarur A., Trivella J. P., Sussman D. A., Drake K., Barkin J. S., Hauenstein S., Deshpande A. R., Quintero M. A., Singh S., van Abreu M. T. Sa1253 Anti-Tumor Necrosis Factor Drug Levels and Anti-Bodies Are Associated With Crohn's Disease Recurrence At the Level of the Ileo-Colonic Anastomosis After Ileal Resection. Gastroenterology 2014 146 S-243-S-244.
51. Steenholdt C., Brynskov J., Thomsen O. O., Munck L. K., Fallingborg J., Christensen L. A., Pedersen G., Kjeldsen J., Jacobsen B. A., Oxholm A. S., Kjellberg J., Bendtzen K., Ainsworth M. A. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: A randomised controlled trial. Gut 2014 63 919-927.
52. Velayos F. S., Kahn J. G., Sandborn W. J., Feagan B. G. A testbased strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin. Gastroenterol Hepatol., 2013 11 654-666.
53. Lopez A., Billioud V., Peyrin-Biroulet C., Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: A systematic review. Inflamm. Bowel Dis., 2013 19 1528-1533.